Background. Mycoplasma hominis, a human urogenital pathogen, is involved in genital and extragenital infections and arthritis, particularly in immunocompromised patients. The interleukin (IL) 23/T helper (Th) 17 axis is associated with inflammatory and autoimmune diseases. The aim of this study was to assess the IL-23 response to M. hominis in human dendritic cells (DCs) and the CD4 1 T-cell differentiation in response to M. hominis-infected DCs.
Mycoplasmas are the smallest self-replicating bacteria that lack cell walls. They harbor bioactive compounds that can trigger inflammatory responses [1] . Mycoplasma hominis is a human mycoplasma that lives as a commensal in the lower urogenital tract. It has been involved in pelvic inflammatory disease, infection during pregnancy, and neonatal infections; occasionally in immunocompromised patients, extragenital infections including arthritis, brain abscess, and pericarditis have been reported [2] . Interestingly, M. hominis has also been found in the synovial fluids or serum samples of individuals with inflammatory disorders including rheumatoid arthritis (RA), raising the possibility of their direct implication in the pathogenesis of autoimmune disorders [3] . Noteworthy, Mycoplasma arthritidis, which is very close phylogenetically to M. hominis, is the causative agent of severe polyarthritis in rats and mice, with similarities to human RA [4] . Thus, studying the interaction between the immune system and human mycoplasmas could help in deciphering their potential role in chronic inflammatory conditions. Dendritic cells (DCs) are a heterogeneous family of cells of hematopoietic origin that are specialized in the handling of antigens. In response to a so-called danger signal, DCs undergo a complex process of maturation into antigen-presenting cells. This happens while the DCs migrate from the periphery into the draining lymph node through the lymphatic system. Within the lymph nodes, through their ability to secrete different cytokines, DCs control T-cell priming [5] . Yet cytokines secreted to induce a specific immune response against an invading pathogen might interfere with DC homeostasis and induce an autoimmune response that can be responsible for tissue pathology. Indeed, clinical and epidemiologic studies have suggested a link between infectious agents and chronic inflammatory disorders, including autoimmune diseases [6] .
Interleukin (IL) 12 and IL-23 are 2 heterodimeric cytokines composed of specific polypeptides, namely, p35 for IL-12 and p19 for IL-23, linked to a common p40 chain to form biologically active molecules. Studies using p19 2/2 or p35 2/2 mouse models of autoimmunity, tumors, and inflammatory bowel disease have identified IL-23, rather than IL-12, as the major factor responsible for lesions caused by chronic inflammation, partially acting through the induction of a CD4 1 T lymphocyte subset producing IL-17 [7] . This T-cell subset has been recently named T-helper (Th) 17 and is identified based on the ability to produce IL-17, IL-21, and IL-22. These T cells have been shown to be major contributors to inflammatory and autoimmune diseases, including ankylosing spondylitis and RA [8] .
Based on this we studied the effect of M. hominis PG21 and different clinical isolates on the activation status of human monocyte-derived DCs. Then we identified the main receptor involved in DCs activation by M. hominis and characterized its bioactive fraction. We observed that M. hominis PG21 as well as M. hominis isolates obtained from different clinical syndromes induced the generation of IL-17-producing T cells, reemphasizing their potential role in chronic inflammatory conditions.
METHODS

Strains and Growth Conditions
The M. hominis type strain PG21 (ATCC 23114) was chosen and grown in Hayflick modified medium supplemented with arginine at 37°C for 48-72 hours [9] . Seven M. hominis clinical isolates were selected from patients with various diseases (Table 1) and stored at 280°C. Rheumatologic strains were isolated from synovial fluids collected from 1991 to 2002 in the Department of Rheumatology of the Bordeaux University Hospital, Bordeaux, France [3] . The present project is in compliance with the Helsinki Declaration. Strains were collected from specimens as part of the patients' usual care without any additional sampling. All patient data shown in the present work are anonymously reported without any possibility of tracing the actual patients. The number of bacteria was evaluated as color-changing units (CCU) in broth media. M. hominis was extensively washed in lipopolysaccharide (LPS)-free phosphate-buffered saline (PBS) and used live or heat inactivated (75°C for 30 minutes), at various concentrations depending on the experiments.
TX-114 Extraction of M. hominis M. hominis components were separated into amphiphilic and hydrophilic fractions, using a slightly modified version of the TX-114 (Boerhinger Mannheim) partitioning method of Bordier [10] . M. hominis was grown to midexponential phase, harvested by centrifugation at 13 000 g for 30 minutes at 4°C, and washed 3 times in PBS. The cells were lysed by sonication on ice 3 times for 1 minute at power level 4 (Vibracell sonicator VC500; Sonics Materials) in PBS. A 10% (wt/vol) solution of TX-114 in Tris-buffered saline (154 mmol/L sodium chloride, 10 mmol/L Tris; pH 7.4) was added to give a final concentration of 1%, and the mixture was incubated for 1 hour at 4°C with gentle rocking. Insoluble cell components were eliminated by centrifugation at 20 000 g for 30 minutes at 4°C. The supernatant was incubated for 10 minutes at 37°C, and the detergent phase was recovered by centrifugation at 12 000 g at room temperature. The upper aqueous phase was transferred to a new tube. Two additional cycles of phase separation were carried out. Proteins from the detergent and aqueous phases were concentrated by precipitation using methanol for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis or acetone for DC stimulation assays. Protein concentration determination was performed using the DC Protein Assay from Bio-Rad. Aliquots were stored at 280°C.
Membrane and Cytosol Extraction
M. hominis was harvested by centrifugation, washed, and lysed as described for TX-114 partitioning, except that sonication was carried out in sterile water. The lysate was centrifuged at 20 000 g for 2 hours at 4°C. The cytosolic fraction (supernatant) was cleared by centrifugation at 20 000 g for 1 hour at 4°C. The pellet corresponding to undisrupted cells and membrane vesicles was resuspended in PBS and submitted to ultrasonication 3 times on ice for 1 minute. Membranes were recovered by centrifugation (20 000 g for 1 hour) and washed 4 times in PBS. An aliquot of each fraction was analyzed by SDS-PAGE under reducing conditions. Proteins were concentrated by acetone precipitation and stored at 280°C.
Generation of DCs and M. hominis Stimulation
Human monocyte-derived DC generation was performed as described elsewhere, using magnetic CD14 microbeads (Miltenyi Biotec) [11] . The purity and viability of DC preparations were .95%. After 5 days of culture, monocyte-derived DCs were transferred into 96-well plates at 2 3 10 5 cells per well along with different doses of M. hominis (from 10 5 to 10 8 CCU/mL, depending on the experiments) and incubated at 37°C for 24-48 hours. DCs were also cultured with 50 lL of PBS (negative control) or in the presence of LPS from Escherichia coli 026:B6 (Sigma, positive control) at a final concentration of 10 ng/mL. In some experiments, cells were exposed to the LPS inhibitor polymyxin B sulfate (Sigma) at 10 lg/mL or to human anti-Toll-like receptor (TLR) 2 blocking antibody (eBiosciences) for 1 hour at 37°C and then exposed to M. hominis for 24 hours. DCs were analyzed using a fluorescence-activated cell sorter (FACS) after 24 hours of incubation with M. hominis. Supernatants were harvested after 24 or 48 hours of coincubation and were stored at 280°C until analysis. They were assessed for cytokine content using Ready-Set-Go enzyme-linked immunosorbent assay (ELISA) kits for the detection of IL-12p70, IL-10, IL23p19, and tumor necrosis factor (TNF) a (eBiosciences). Data were processed with the Biolise 2.0 software.
FACS Analysis of DC Cell Surface Molecules
For immunophenotyping, DCs were washed in PBS and incubated at 4°C with one of the following human monoclonal antibodies: anti-CD80-phycoerythrin (PE), anti-CD-86-PE, anti-HLA-DR-PE-cyanine (Cy) 5, anti-CD40-PE, anti-CD83-PE, or anti-CD1a-fluorescein isothiocyanate (FITC) (eBiosciences). The appropriate isotype controls were included. After washing, 10 4 cells were analyzed on a FACSCalibur flow cytometer (Becton Dickinson). Data were processed with the CellQuest cytometry software (BD Biosciences). The expression of the cell surface molecules was either shown as 1parameter histograms or evaluated using mean fluorescence intensity.
Mixed-Lymphocyte Reaction
DCs coincubated with PBS, LPS, or M. hominis were harvested after 24 hours of incubation, and free stimuli were removed by washing 2 times with RPMI1640. Mixed-lymphocyte reactions using viable, cryopreserved total allogenic T lymphocytes were conducted as described elsewhere [11] .
Intracellular Flow Cytometry Detection of Cytokine Production by Allogenic CD4 1 T Cells CD3 1 T cells were purified from the CD14-negative fraction using indirect magnetic cell labeling with an anti-CD3-FITC antibody and anti-FITC microbeads (Miltenyi Biotec). Monocytederived DCs coincubated with PBS, LPS, or M. hominis PG21 for 24 hours were used to stimulate allogenic T cells at a ratio of 1:1 for 5 days. For intracellular cytokine staining, cells were incubated for 5 hours with phorbol myristate acetate (50 ng/mL; Sigma), ionomycin (500 ng/mL; Sigma), and brefeldin A (10 lg/mL; Sigma). Cells were stained for surface CD4 expression by incubation for 15 minutes at 4°C with an anti-CD4-PE-Cy5 antibody (eBioscience). Cells were fixed and permeabilized for 20 minutes at 4°C using the Cytofix/Cytoperm buffer set (Becton Dickinson) and were stained for 30 minutes at 4°C in permeabilization buffer with anti-interferon (IFN) c-FITC and anti-IL-17A-PE antibodies (eBiosciences). The cells were analyzed using a Becton Dickinson FACSCANTO instrument. Data were analyzed using the FACSDIVA 6.1.3 software.
Taqman Real-Time Polymerase Chain Reaction for IL-23p19 and IL-12p35 RNA Total RNA was isolated from 1 3 10 5 to 10 6 cells using a Total RNA Isolation Reagent kit (Ademtech). RNA was precipitated in isopropanol, resuspended in 30 lL of RNase-free water and quantified using a Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies). In summary, 1-10 pg of total RNA was reverse-transcribed to complementary DNA (cDNA) with the Verso cDNA Kit (Thermo Scientific ABgene), according to the manufacturer's instructions. The cDNA was amplified and quantified using the Taqman real-time polymerase chain reaction assay described for human IL-12p35 and IL-23p19 by Lee et al [12] . The real-time polymerase chain reaction mixture consisted of 10 lL of 23 LightCycler 480 Probes Master (Roche Diagnostics), 0.6 lL of each primer (10 lmol/L), 0.8 lL of each of the 3 probes (5 lmol/L), and 3 lL of cDNA as template. We used a Roche LightCycler 480 thermocycler for 15 minutes at 95°C, followed by 45 cycles of 10 seconds at 95°C and 60 seconds at 60°C. Each sample was normalized to the human acidic ribosomal protein gene (hARP) by obtaining the difference in threshold cycle (Ct) number between hARP and the cytokines. Relative RNA (messenger RNA [mRNA]) expression levels were calculated using the formula 2 2DDCT , where the Ct of the target gene is normalized to the gene expression of the control condition.
Statistical Analyses
Data are expressed as means 6 standard deviations, and the significance of differences between 2 series of results was determined using Student unpaired t test. Differences were considered significant at P # .05.
RESULTS
Morphologic, Phenotypic, and Functional Maturation of Human DCs by M. hominis PG21
To analyze the potential immunomodulatory activity of M. hominis toward human DCs, preparations of PBS, LPS, or M. hominis PG21 were added to 5 day-cultured monocyte-derived DCs. Different culture conditions were tested to find the optimal dose and incubation time. M. hominis was used live or heat-inactivated at several concentrations, 10 5 -10 8 CCU/mL, and incubated with DCs for 24 or 48 hours. No significant difference was seen between live and heat-inactivated M. hominis or between different incubation times (data not shown). The conditions used in further experiments were live M. hominis cells at 10 8 CCU/mL for 24 hours. After incubation, DCs were collected and observed after centrifugation by light microscopy. Both LPS and M. hominis induced the development of widespread cytoplasmic projections called dendrites (Figure 1) , reflecting a morphologic maturation. The surface expression of HLA-DR, CD80, CD83, CD86, and CD40 were analyzed by FACS ( Figure 1B cocultured with allogenic total lymphocytes for 5 days at a 1:100 ratio. LPS and M. hominis activation of DCs markedly enhanced lymphocyte proliferation (P , .01) ( Figure 1C ).
M. hominis PG21 Increases DC Inflammatory Cytokine Production Including Predominant IL-23 Secretion in a TLR2-Dependent Manner
Because DCs are known to play key roles in the integration of environmental signals and polarization of the adaptive immune response, the production of several cytokines (TNF-a, IL-10, IL-12, and IL-23) by M. hominis-activated DCs was tested. No bioactive cytokines were detectable in the cell culture supernatants of PBS-stimulated DCs. M. hominis PG21 consistently induced TNF-a, IL-10, and IL-23. There was significantly higher production of IL-23 by M. hominis-treated DCs as compared with LPS-treated DCs (Figure 2A ) (P , .05). Interestingly, in the presence of M. hominis PG21, very low IL-12 production by DCs was detected, whereas LPS induced the secretion of both IL-23 and IL-12 ( Figure 2A ) ( P , .01). These results were further confirmed by the detection of IL-23 mRNA, but not IL-12 mRNA, in DCs incubated with M. hominis ( Figure 2B) . A previous study showed that M. hominis induced TNF-a production by human monocytes in a TLR2-but not TLR4-dependent manner [13] . Therefore, we wanted to determine whether TLR2 was involved in IL-23 production by human DCs activated by M. hominis. As shown in Figure 2C , blocking anti-TLR2 antibodies inhibited M. hominis-induced IL-23 production.
In Vitro Immunomodulatory Capacity of M. hominis Residing in Membrane-Associated Proteins Different M. hominis protein extracts were assayed for their ability to induce cytokine production by human DCs. The protein fractions that were tested corresponded to the membrane-enriched and cytosolic fractions isolated by differential centrifugation and to the detergent-soluble and aqueous phases separated by TX-114 phase partitioning. The complementarity of the electrophoresis profiles obtained from the TX-114-soluble and aqueous phases was examined ( Figure 3A) . Similar to the whole cells of M. hominis, the detergent-soluble and membrane-enriched phases induced a significant increase in production of TNF-a, IL-10, and IL-23 by human DCs. In contrast, the cytosolic and TX-114 aqueous phases only weakly modulated the cytokine profiles ( Figure 3B ). Hence, M. hominis membrane-associated amphiphilic proteins were mainly responsible for the induction of cytokine production by DCs. To exclude potential LPS contamination, the effects of prior treatment with polymyxin B, an inhibitor of LPS-mediated stimulation, on the ability of the different extracts to activate DCs were assessed. The activity of membrane and detergent-enriched fractions was not reduced by polymyxin B, whereas it dramatically inhibited LPS activity by about 95% ( Figure 3C ) (P , .01). Considering the prominent secretion of IL-23 by M. hominis PG21-stimulated DCs, we next examined whether these DCs were able to induce IL-17-secreting cells. This ability was assessed by measuring intracellular IFN-c and IL-17 production by gated CD4 1 T cells among CD3 1 T cells cultured along with M. hominis PG21-stimulated DCs. Figure 4A shows a representative result obtained from 1 experiment of 7. In comparison with PBS-or LPS-treated DCs, DCs activated by M. hominis induced a significantly higher percentage of IL-17-positive CD4 1 T cells ( Figure 4B) (P , .05 ).
Variable Ability of M. hominis Clinical Isolates to Induce IL-23 Secretion by DCs
Seven strains isolated from different clinical syndromes were studied ( Table 1 ). Six isolates were obtained from synovial fluids of patients suffering from inflammatory or noninflammatory rheumatologic diseases (isolates 1-6), and the last isolate was obtained from a patient with endometritis (isolate 7). IL-23, IL-10, IL-12, and TNF-a production were measured in the supernatants of DCs cultured with each of the 7 isolates by ELISA after 24 hours of incubation. Secretion of TNF-a and IL-10 was equivalent in all isolates (data not shown), and the IL-12 secretion was even lower than that induced by PG21 for all isolates except for the osteoarthritis isolate (isolate 5). Interestingly, compared with PG21, the IL-23 secretion induced by the clinical isolates was very variable ( Figure 5A ) ranging from 172 6 59 pg/mL for isolate 5 to 1946 6 300 pg/mL for isolate 7. When the IL-23/IL-12 ratio was considered, differences among these isolates were strongly reinforced. As seen in Figure 5B , this ratio was significantly lower for the osteoarthritis isolate (isolate 5) and higher for the endometritis isolate (isolate 7) than for M. hominis PG21. Moreover, it was significantly higher for the hypogammaglobulinemia arthritis isolate (isolate 6) than for the osteoarthritis isolate (isolate 5) (P # .05). No significant difference was shown between M. hominis PG21 and the 5 other clinical isolates. Taken as a whole, this set of data suggests that different M. hominis strains have different abilities to activate the innate immune system.
DISCUSSION
We studied the effects of M. hominis PG21 on the maturation and activation of human monocyte-derived DCs. We observed that the production of IL-23 by DCs was enhanced by M. hominis PG21 in a TLR2-dependent manner, thereby promoting the skewing of T cells toward IL-17-producing cells. We also showed that this biologic effect was mainly contained in the membrane lipoproteins of M. hominis. Unexpectedly, when testing the IL-23/IL-12 production by several clinical isolates, the results differed according to the isolate origin, suggesting differential ability to induce IL-17-producing cells.
Here, we not only confirmed that M. hominis promoted secretion of IL-10 and low IL-12 by human monocytes [13] and DCs [14] but extend the observation with the strong ability of M. hominis to induce IL-23 secretion in a TLR2-dependent fashion. This is in accordance with the description by Peltier et al [13] of a TLR2-dependent secretion of TNF-a by M. hominisstimulated human monocytes. TLR2 ligands, including Pam2C, are known to inhibit IL-12 and increase IL-23 production by monocyte-derived DCs. Accordingly, TLR2 can be viewed as a key pattern recognition receptor that differentially regulates the expression of these 2 cytokines [15] . Interestingly, other mycoplasma species have been described to activate either DCs or monocytes through TLR2. As an example, M. arthritidis, an arthritis inducer in rodents, also presents antigenic lipoproteins, including M. arthritidis mitogen (MAM), that induce TNF-a secretion by murine DCs through TLR2 [16] . It should be noted that no homolog of the MAM gene has been identified in the complete genome sequence of M. hominis [17] . Mycoplasma pneumoniae, a human respiratory pathogenic mycoplasma, harbors lipid-associated membrane proteins on its surface that drive murine monocytes to secrete IL-23 via a heterodimer formed by TLR2 and TLR1 or TLR6 [18, 19] . The macrophageactivating lipopeptide-2 (MALP-2) of Mycoplasma fermentans, a human urogenital mycoplasma, induces proinflammatory cytokine secretion by human monocytes and IL-10 secretion by DCs via TLR2 and TLR6 [20, 21] .
Phase partitioning of M. hominis components with TX-114 indicated that the activity of M. hominis could be mainly attributed to the fraction containing amphiphilic, membraneassociated proteins. In mycoplasmas, TX-114-soluble fractions are enriched in lipoproteins [10] , and the active fraction for stimulating DCs may correspond to one or several lipoproteins. Indeed, the immunomodulatory activity of lipoproteins has already been observed for M. hominis [13] and other Mycoplasma species [16, 20] . Additional experiments will be required to identify the human DC-activating components of M. hominis.
Unexpectedly, we observed that M. hominis from different clinical isolates displayed different potentials to promote the secretion of IL-12 and IL-23 by DCs. This difference in virulence has been already observed in other Mycoplasma strains. Indeed, Cole et al [16] have used M. arthritidis strains exhibiting different degrees of virulence to show that the virulent strain of M. arthritidis was more potent in activating murine DCs than an avirulent strain. Interestingly, the highest DC-induced IL-23/IL-12 ratio was found with isolate 7 obtained from an inflammatory syndrome, an endometritis, and was significantly higher than that obtained with M. hominis PG21. In contrast, the lowest IL-23/IL-12 ratio, significantly lower than that of PG21, was obtained from a noninflammatory noninfectious clinical disease (isolate 5, osteoarthritis). It should be noted that all the other tested isolates induced a DC-secreted IL-23/IL-12 ratio not significantly different from that of M. hominis PG21. A mixture of virulent and less virulent strains cannot be eliminated, and the different isolates should be cloned to confirm our findings. Moreover, these observations question the consequences of the different IL-23/IL-12 ratios with regard to the ability of these isolates to induce IL-17 production by T lymphocytes. We are currently investigating these particular issues.
IL-23, in combination with other cytokines such as IL-6 and transforming growth factor (TGF) b, is involved in Th17 differentiation that is essential for the defense against fungi, extracellular bacteria, and Mycobacterium tuberculosis [22] [23] [24] . Recent findings in mice showed that Th17 cells could be generated directly by IL-23 without TGF-b [25] . IL-23 might also contribute to the defense against M. pneumoniae [18] and M. arthritidis [26] in mice, but little is known about the role of this cytokine in the defense against mycoplasmas in humans. Thus, our results confirm the ability of M. hominis-induced IL-23 production to promote the up-regulation of IL-17Aproducing cells in humans.
There is compelling evidence for the involvement of Th17 cells in mouse and human autoimmune diseases. Mycoplasmas have been suspected to be involved in inflammatory chronic autoimmune diseases, including RA, through their antigenic plasticity and/or through molecular mimicry [27] . The fact that mycoplasmas can be found in synovial specimens from patients with RA and the ability of mycoplasmas to induce IL-17A production necessitates to consider again mycoplasmas in the pathogenic landscape of inflammatory disorders [28] . Collectively, our findings delineate a major role for the IL-23/Th17 axis in the defense against M. hominis and point to the potential implication of some isolates of M. hominis in the occurrence of flares in IL-17-mediated chronic disorders. 
